Genomic instability is a hallmark of cancer where the acquisition of numerous genetic alterations leads to transformation and carcinogenesis. These alterations result in the generation of potentially immunogenic neoantigens, and the clinical success of checkpoint inhibitor therapies has highlighted the importance of neoantigens in cancer immunotherapy. Evaluation of the next generation of neoantigen therapies is complicated by the difficulty in sourcing primary patient material.
